Machine Learning Framework for Implementing Alzheimer’s Disease

Author(s):  
R. Sivakani ◽  
Gufran Ahmad Ansari
2021 ◽  
pp. 423-432
Author(s):  
Sean A. Knox ◽  
Tianhua Chen ◽  
Pan Su ◽  
Grigoris Antoniou

Author(s):  
N. Vinutha ◽  
S. Pattar ◽  
S. Sharma ◽  
P. D. Shenoy ◽  
K.R. Venugopal

The neuropsychological scores and Functional Activities Questionnaire (FAQ) are significant to measure the cognitive and functional domain of the patients affected by the Alzheimer’s Disease. Further, there are standardized dataset available today that are curated from several centers across the globe that aid in development of Computer Aided Diagnosis tools. However, there are numerous clinical tests to measure these scores that lead to a challenging task for their assessment in diagnosis. Also, the datasets suffer from common missing and imbalanced data issues. In this paper, we propose a machine learning based framework to overcome these issues. Empirical results demonstrate that improved performance of Genetic Algorithm is obtained for the neuropsychological scores after Miss Forest Imputation and for FAQ scores is obtained after subjecting it to the Synthetic Minority Oversampling Technique.


2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Steve Rodriguez ◽  
Clemens Hug ◽  
Petar Todorov ◽  
Nienke Moret ◽  
Sarah A. Boswell ◽  
...  

AbstractClinical trials of novel therapeutics for Alzheimer’s Disease (AD) have consumed a large amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA) for another indication is a more rapid and less expensive option. We present DRIAD (Drug Repurposing In AD), a machine learning framework that quantifies potential associations between the pathology of AD severity (the Braak stage) and molecular mechanisms as encoded in lists of gene names. DRIAD is applied to lists of genes arising from perturbations in differentiated human neural cell cultures by 80 FDA-approved and clinically tested drugs, producing a ranked list of possible repurposing candidates. Top-scoring drugs are inspected for common trends among their targets. We propose that the DRIAD method can be used to nominate drugs that, after additional validation and identification of relevant pharmacodynamic biomarker(s), could be readily evaluated in a clinical trial.


2016 ◽  
Vol 13 (5) ◽  
pp. 498-508 ◽  
Author(s):  
V. Vigneron ◽  
A. Kodewitz ◽  
A. M. Tome ◽  
S. Lelandais ◽  
E. Lang

Processes ◽  
2020 ◽  
Vol 8 (9) ◽  
pp. 1071
Author(s):  
Lucia Billeci ◽  
Asia Badolato ◽  
Lorenzo Bachi ◽  
Alessandro Tonacci

Alzheimer’s disease is notoriously the most common cause of dementia in the elderly, affecting an increasing number of people. Although widespread, its causes and progression modalities are complex and still not fully understood. Through neuroimaging techniques, such as diffusion Magnetic Resonance (MR), more sophisticated and specific studies of the disease can be performed, offering a valuable tool for both its diagnosis and early detection. However, processing large quantities of medical images is not an easy task, and researchers have turned their attention towards machine learning, a set of computer algorithms that automatically adapt their output towards the intended goal. In this paper, a systematic review of recent machine learning applications on diffusion tensor imaging studies of Alzheimer’s disease is presented, highlighting the fundamental aspects of each work and reporting their performance score. A few examined studies also include mild cognitive impairment in the classification problem, while others combine diffusion data with other sources, like structural magnetic resonance imaging (MRI) (multimodal analysis). The findings of the retrieved works suggest a promising role for machine learning in evaluating effective classification features, like fractional anisotropy, and in possibly performing on different image modalities with higher accuracy.


Author(s):  
M. Tanveer ◽  
B. Richhariya ◽  
R. U. Khan ◽  
A. H. Rashid ◽  
P. Khanna ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document